Exelixis, Inc.'s STELLAR-303 zanzalintinib data disappoints in colorectal cancer with an FDA decision due in December 2026.
The Income Tax Department has made the Excel Utility for ITR-5 available for Assessment Year (AY) 2026-27, allowing eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results